dimethyl[4-(6-methylquinolin-2-yl)phenyl]amine | 30479-21-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: dimethyl[4-(6-methylquinolin-2-yl)phenyl]amine
• 英文别名: N,N-dimethyl-4-(6-methyl-quinolin-2-yl)-aniline；N,N-dimethyl-4-(6-methyl-[2]quinolyl)-aniline；N,N-Dimethyl-4-(6-methyl-[2]chinolyl)-anilin；N,N-dimethyl-4-(6-methyl-2-quinolyl)aniline；N,N-dimethyl-4-(6-methylquinolin-2-yl)aniline
• CAS: 30479-21-1
• 化学式: C₁₈H₁₈N₂
• 分子量: 262.354
• InChiKey: RWZFLILFUOBPIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6-甲基喹啉 、 [4-(二甲基氨基)苯基]锂 在 乙醚 作用下， 生成 dimethyl[4-(6-methylquinolin-2-yl)phenyl]amine
  参考文献：
  名称：

  一些甲基喹啉图案化为atebrin的开放模型。

  摘要：

  DOI：

  10.1021/ja01214a044

文献信息

• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• ONO pincer type Pd(<scp>ii</scp>) complexes: synthesis, crystal structure and catalytic activity towards C-2 arylation of quinoline scaffolds
  作者：Vignesh Arumugam、Werner Kaminsky、Dharmaraj Nallasamy

  DOI：10.1039/c5ra15342e

  日期：——

  Four new palladium(ii) complexes featuring ONO pincer type hydrazone ligands were synthesized and characterized by spectroscopic and single-crystal XRD analysis. Utility of these complexes to catalyze C–C bond formation in quinoline scaffolds were assessed.

  四种新的钯（II）配合物，具有ONO钳夹式腙配体，经过光谱和单晶XRD分析合成并表征。评估了这些配合物在喹啉骨架中催化C-C键形成的实用性。
• Imaging Agents for Detecting Neurological Disorders
  申请人：Szardenings Anna Katrin

  公开号：US20110182812A1

  公开（公告）日：2011-07-28

  Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

  本文介绍了公式（I）-（V）的成像剂和用于检测神经系统疾病的方法，其中包括向需要治疗的患者注射能够结合tau蛋白和β-淀粉样肽的公式（I）-（V）化合物。本发明还涉及成像Aβ和tau聚集物的方法，包括引入含有放射性标记的公式（I）-（V）化合物的制剂，并检测与淀粉样沉积物和/或tau蛋白相关联的标记化合物。这些方法和组合物可用于预临床诊断和监测AD和其他神经系统疾病的进展。
• Koslow; Pinegina, Zhurnal Obshchei Khimii, 1957, vol. 27, p. 1965; engl. Ausg. S. 2026
  作者：Koslow、Pinegina

  DOI：——

  日期：——
• [EN] TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE<br/>[FR] PROTACS CIBLANT LA PROTÉINE TAU ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：ARVINAS INC

  公开号：WO2018102067A2

  公开（公告）日：2018-06-07

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.